However, about 35% of MDM2/MDMX co-amplifications co-exist with p53 deletion or mutation, suggesting that they may also have a p53-independent oncogenic function in CRPC prostate cancer (Figure 1A). This evidence concerns the gene TP53 and prostate carcinoma.